Tawata M, Aida K, Noguchi T, Ozaki Y, Kume S, Sasaki H, Chin M, Onaya T
Third Department of Internal Medicine, University of Yamanashi Medical School, Japan.
Eur J Pharmacol. 1992 Feb 25;212(1):87-92. doi: 10.1016/0014-2999(92)90076-g.
The mechanism was studied by which isoliquiritigenin, a new aldose reductase inhibitor purified from licorice (Glycyrrhizae radix), inhibits platelet aggregation. This new agent significantly inhibited the phosphorylation of 40,000- and 20,000-dalton proteins, and inhibited the formation of 12 (S)-hydroxy-5,8,10-heptadecatrienoic acid, 12-hydroxyeicosatetraenoic acid and thromboxane B2. The inhibitory effect of isoliquiritigenin on platelet aggregation in vitro was comparable to that of aspirin. Our findings may indicate that isoliquiritigenin elicits an anti-platelet action by inhibiting not only cyclooxygenase but also lipoxygenase or peroxidase activity in platelets. Isoliquiritigenin also showed an anti-platelet action in vivo. Isoliquiritigenin appears to be the only aldose reductase inhibitor with a significant anti-platelet action. Since the hyperaggregability of platelets has been implicated in the pathogenesis of diabetic complications, isoliquiritigenin may offer a unique benefit as an aldose reductase inhibitor.
对从甘草（甘草根）中纯化得到的新型醛糖还原酶抑制剂异甘草素抑制血小板聚集的机制进行了研究。这种新药显著抑制了40000道尔顿和20000道尔顿蛋白质的磷酸化，并抑制了12（S）-羟基-5,8,10-十七碳三烯酸、12-羟基二十碳四烯酸和血栓素B2的形成。异甘草素在体外对血小板聚集的抑制作用与阿司匹林相当。我们的研究结果可能表明，异甘草素不仅通过抑制环氧化酶，还通过抑制血小板中的脂氧化酶或过氧化物酶活性来发挥抗血小板作用。异甘草素在体内也表现出抗血小板作用。异甘草素似乎是唯一具有显著抗血小板作用的醛糖还原酶抑制剂。由于血小板的高聚集性与糖尿病并发症的发病机制有关，异甘草素作为一种醛糖还原酶抑制剂可能具有独特的益处。
